Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015
GlobalData, the industry analysis specialist’s new report, “Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015” is an essential source of information and analysis on the global Hepatitis B vaccines market. The report identifies the key trends shaping and driving the global Hepatitis B vaccines market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Hepatitis B vaccines sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
GlobalData estimates the global Hepatitis B vaccines market to be $1.1 billion in 2008. It is forecast to grow at 7% annually for the next seven years to reach $1.8 billion by 2015. This growth is primarily attributed to growth in the adult vaccines market as a result of increasing awareness among people. The market will be primarily driven by increasing population growth and lack of other effective options for prevention against the disease. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the unmet needs. There is enormous opportunity for any vaccine that would offer better or retain the efficacy provided by the current players with increased safety than the current products.
GlobalData finds that that the competitive landscape is likely to remain static in the future. Majority of the promising pipeline products belong to the same class as the existing products offering minute improvements in the safety and efficacy profiles. This allows the existing market leaders to maintain their position as they won’t face any significant challenges in maintaining their market shares. Companies offering therapeutic vaccines may change the competitive landscape if the safety and efficacy of these vaccines is proven.
Scope
The report analyzes market opportunities and challenges for the global Hepatitis B vaccines market. Its Scope includes
- Annualized global Hepatitis B vaccines market revenues data from 2005 to 2008, forecast forward for 7 years to 2015.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different vaccine classes. Key vaccine classes include prophylactic vaccines and therapeutic vaccines.
- Analysis of the current and future market competition in the global Hepatitis B vaccines market. Key market players covered are GlaxoSmithKline, Merck, Dynavax Technologies, Pfizer, Emergent Biosoloutions, PepTcell and Celldex Therapeutics.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Hepatitis B vaccines.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Hepatitis B vaccines market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Hepatitis B vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Hepatitis B vaccines market landscape? – Identify, understand and capitalize.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
GlobalData estimates the global Hepatitis B vaccines market to be $1.1 billion in 2008. It is forecast to grow at 7% annually for the next seven years to reach $1.8 billion by 2015. This growth is primarily attributed to growth in the adult vaccines market as a result of increasing awareness among people. The market will be primarily driven by increasing population growth and lack of other effective options for prevention against the disease. The available treatment options are moderately successful in meeting the market demand. There exists a significant market potential to be tapped for any new entrant that will cater to the unmet needs. There is enormous opportunity for any vaccine that would offer better or retain the efficacy provided by the current players with increased safety than the current products.
GlobalData finds that that the competitive landscape is likely to remain static in the future. Majority of the promising pipeline products belong to the same class as the existing products offering minute improvements in the safety and efficacy profiles. This allows the existing market leaders to maintain their position as they won’t face any significant challenges in maintaining their market shares. Companies offering therapeutic vaccines may change the competitive landscape if the safety and efficacy of these vaccines is proven.
Scope
The report analyzes market opportunities and challenges for the global Hepatitis B vaccines market. Its Scope includes
- Annualized global Hepatitis B vaccines market revenues data from 2005 to 2008, forecast forward for 7 years to 2015.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different vaccine classes. Key vaccine classes include prophylactic vaccines and therapeutic vaccines.
- Analysis of the current and future market competition in the global Hepatitis B vaccines market. Key market players covered are GlaxoSmithKline, Merck, Dynavax Technologies, Pfizer, Emergent Biosoloutions, PepTcell and Celldex Therapeutics.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Hepatitis B vaccines.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Hepatitis B vaccines market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Hepatitis B vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Hepatitis B vaccines market landscape? – Identify, understand and capitalize.
Contents
1 TABLE OF CONTENTS
1.1 LIST OF TABLES
1.2 LIST OF FIGURES
1.3 Overview
1.4 Hepatitis B Vaccines Market Size
1.5 Hepatitis B Vaccines Market Forecast and CAGR
1.6 Drivers and Barriers for Hepatitis B Vaccines Market
1.6.1 Drivers for Hepatitis B Vaccines Market
1.6.2 Barriers for Hepatitis B Vaccines Market
1.7 Opportunity and Unmet Need
1.8 Key Takeaway
2 HEPATITIS B VACCINES MARKET: COMPETITIVE ASSESSMENT
2.1 Overview
2.2 Strategic Competitor Assessment
2.3 Product Profile for the Major Marketed Vaccines in Hepatitis B Market
2.3.1 Recombivax HB
2.3.2 Engerix-B
2.3.3 Twinrix
2.3.4 Comvax
2.4 Major Marketed Products Comparison in Hepatitis B Vaccines Market
2.5 Key Takeaway
3 HEPATITIS B VACCINES MARKET: PIPELINE ASSESSMENT
3.1 Overview
3.2 Strategic Pipeline Assessment
3.2.1 Technology Trends Analytical Framework
3.3 Hepatitis B Vaccines Therapeutics –Promising Vaccines under Clinical Development
3.4 Molecule Profile for Promising Vaccines under Clinical Development
3.4.1 Heplisav
3.4.2 Spi-VEC
3.5 Hepatitis B Vaccines Market – Clinical Pipeline by Vaccine Class
3.6 Hepatitis B Vaccines Pipeline – Pipeline by Clinical Phases of Development
3.6.1 Hepatitis B Vaccines Therapeutics – Phase III Clinical Pipeline
3.6.2 Hepatitis B vaccines Therapeutics – Phase II Clinical Pipeline
3.6.3 Hepatitis B Vaccines Therapeutics – Phase I Clinical Pipeline
3.6.4 Hepatitis B Vaccines Therapeutics – Preclinical Pipeline
3.6.5 Hepatitis B vaccines Therapeutics – Discovery Pipeline
3.7 Discontinued / Suspended Vaccines for Hepatitis B
3.8 Key Takeaway
4 GLOBAL HEPATITIS B VACCINES MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION
5 GLOBAL HEPATITIS B VACCINES MARKET: FUTURE PLAYERS IN HEPATITIS B VACCINES MARKET
5.1 Introduction
5.2 GlaxoSmithKline
5.2.1 Company Overview
5.2.2 Business Description
5.3 Dynavax Technologies
5.3.1 Company Overview
5.3.2 Business Description
5.4 Emergent BioSolutions Inc.
5.4.1 Company Overview
5.4.2 Business Description
5.5 PepTcell Limited
5.5.1 Company Overview
5.5.2 Business Description
5.6 Celldex Therapeutics, Inc.
5.6.1 Company Overview
5.6.2 Business Description
5.7 Pfizer
5.7.1 Company Overview
5.7.2 Business Description
6 GLOBAL HEPATITIS B VACCINES MARKET: APPENDIX
6.1 Definitions
6.2 Acronyms
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Primary Research
6.3.5 Expert Panel Validation
6.4 Contact Us
6.5 Disclaimer
6.6 Sources
1.1 LIST OF TABLES
Table 1: Global Hepatitis B Vaccines Market, Revenues ($m), 2005-
Table 2: Global Hepatitis B Vaccines Market, Revenues ($m), 2009-
Table 3: Major Marketed Products Comparison in Hepatitis B Vaccines Market,
Table 4: Hepatitis B Vaccines Therapeutics – Most Promising Vaccines Under Clinical Development,
Table 5: Hepatitis B Vaccines Therapeutics – Phase III Clinical Pipeline,
Table 6: Hepatitis B Vaccines Therapeutics – Phase II Clinical Pipeline,
Table 7: Hepatitis B Vaccines Therapeutics – Phase I Clinical Pipeline,
Table 8: Hepatitis B Vaccines Therapeutics – Preclinical Pipeline,
Table 9: Hepatitis B Vaccines Therapeutics – Discovery Pipeline,
TABLE 10: LIST OF DISCONTINUED VACCINES FOR HEPATITIS B,
1.2 LIST OF FIGURES
Figure 1: Global Hepatitis B Vaccines Market, Revenues ($m), 2005-
Figure 2: Opportunity and Unmet Need in the Hepatitis B Vaccines Market,
Figure 3: Strategic Competitor Assessment of the Hepatitis B Vaccines Market,
Figure 4: Technology Trends Analytic Framework-Hepatitis B Vaccines Market,
Figure 5: Technology Trends Analytic Framework – Description- Hepatitis B Vaccines Market,
Figure 6: Hepatitis B Vaccines Therapeutics Market – Clinical Pipeline by Class of Vaccine,
Figure 7: Hepatitis B Vaccines Pipeline by Phase of Clinical Development,
Figure 8: Implications For Future Market Competition in the Hepatitis B Vaccines Market,
Figure 9: Hepatitis B Vaccines Therapeutics Market – Clinical Pipeline by Company,
Figure 10: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model
GlaxoSmithKline
Merck
Dynavax Technologies
Pfizer
Emergent Biosoloutions
PepTcell
Celldex Therapeutics.
Skip to top